Search

XALKORI 200 MG, Gélule

Details

--- Description
Pack Boîte de 60
Strength (Dosage) 200 MG
Laboratory PFIZER MAROC
Ingredients Crizotinib
Therapeutic class Antinéoplasique, inhibiteur de la tyrosine kinase
ATC code L01XE16
PPH $4,677.40
PPV $4,770.10
Refundable No
Refund base $0.00
Refund rate $0.00
Table A
Marketing status Commercialized
Type Medication
Uses Xalkori est indiqué en première ligne de traitement des patients adultes ayant un cancer du poumon non à petites cellules (CPNPC) anaplastic lymphoma kinase (ALK) positif et avancé. XALKORI® est indiqué dans le traitement des patients adultes ayant reçu au moins un traitement antérieur pour un cancer du poumon non à petites cellules (CPNPC) anaplastic lymphoma kinase (ALK)-positif et avancé. XALKORI® est indiqué dans le traitement des patients adultes ayant un cancer du poumon non à petites cellules (CPNPC) ROS1 (Proto-Oncogene 1, Receptor Tyrosine Kinase)-positif et avancé.
Warnings
Dosage
Avoid
Side effects
Interactions

Medications under one or more of the therapeutic classes above


Medications from the same laboratory


Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.